Company intelligence / Profile preview

Kopra Bio

San Francisco, California, United Stateskopra.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Kopra Bio has demonstrated that its lead viral immunotherapy candidate can increase survival rates from 0% with standard-of-care to over 90% in preclinical mouse models of glioblastoma. The company is now extending proof-of-concept work to other solid tumor types including breast, ovarian, and colon cancers. No clinical trial results are available yet.

Therapeutic areas: Oncology
Modalities: Genetically engineered viruses (viral immunotherapy)Gene therapy (implied by viral vector approach)
Industry: Biotech

Drug pipeline

1 asset

RRV RLI

Preclinical

Partnerships

QB3 mentoring program/grant support [awarded $100K grant from QB3 accelerator at UCSF].

Beyond the preview

Go deeper on Kopra Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kopra Bio.

Explore the full profile